Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

I. Scher, Howard; J. Morris, Michael; M. Stadler, Walter; Higano, Celestia; Basch, Ethan; Fizazi, Karim; S. Antonarakis, Emmanuel; M. Beer, Tomasz; A. Carducci, Michael; N. Chi, Kim; G. Corn, Paul; S. de Bono, Johann; Dreicer, Robert; J. George, Daniel; I. Heath, Elisabeth; Hussain, Maha; Kevin Kelly, Wm.; Liu, Glenn; Logothetis, Christopher; Nanus, David; N. Stein, Mark; E. Rathkopf, Dana; F. Slovin, Susan; J. Ryan, Charles; Sartor, Oliver; J. Small, Eric; Raymond Smith, Matthew; N. Sternberg, Cora; Taplin, Mary-Ellen; Wilding, George; S. Nelson, Peter; H. Schwartz, Lawrence; Halabi, Susan; W. Kantoff, Philip; J. Armstrong, Andrew

doi:10.1200/jco.2015.64.2702

Public

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

Shared by NobleBlocks on Apr 20, 2016 • 12:00 AM UTC

Authors:

Howard I. Scher

Michael J. Morris

Walter M. Stadler

Abstract

Purpose Evolving treatments, disease phenotypes, and biology, together with a changing drug development environment, have created the need to revise castration-resistant prostate cancer (CRPC) clinical trial recommendations to succeed those from prior Prostate Cancer Clinical Trials Working Groups. ...

Discussions